nitrofurantoin has been researched along with ethambutol in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (26.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (53.33) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dobson, RA; Johnson, RE; O'Connor, JR; Soria, AE | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Cho, SH; Franzblau, SG; Hwang, CH; Pauli, GF; Wan, B; Warit, S | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Kimbel, KH | 1 |
| Jackson, EA; McLeod, DC | 1 |
| van Cauwenberge, H | 1 |
| Kibadi, K | 1 |
1 review(s) available for nitrofurantoin and ethambutol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
14 other study(ies) available for nitrofurantoin and ethambutol
| Article | Year |
|---|---|
Synthesis and antibacterial activity of 1-(arylamino)-1H-pyrroles and 4-(1H-pyrrol-1-ylimino)-2,5-cyclohexadienes.
Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Biotransformation; Chemical Phenomena; Chemistry; Cyclohexanes; Female; Mice; Pyrroles; Rats; Rats, Inbred Strains | 1981 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Antitubercular Agents; DNA, Bacterial; Drug Evaluation, Preclinical; Mycobacterium tuberculosis; Oxygen | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
[Toxicological evaluation criteria (secondary action aspects)].
Topics: Anti-Infective Agents; Cephalosporins; Chloramphenicol; Erythromycin; Ethambutol; Gentamicins; Humans; Isoniazid; Lincomycin; Nalidixic Acid; Neomycin; Nitrofurantoin; Penicillins; Rifampin; Streptomycin; Sulfonamides; Tetracyclines | 1977 |
Pharmacokinetics and dosing of antimicrobial agents in renal impairment, Part II.
Topics: Anti-Infective Agents; Bacitracin; Chloramphenicol; Chloroquine; Clindamycin; Dapsone; Ethambutol; Humans; Isoniazid; Kidney Diseases; Methenamine; Nalidixic Acid; Neomycin; Nitrofurantoin; Sulfadimethoxine; Sulfamethizole; Sulfamethoxazole; Sulfamethoxypyridazine; Sulfisomidine; Sulfisoxazole; Vancomycin | 1974 |
[Current therapeutics in clinical medicine].
Topics: Anti-Bacterial Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Cephalosporins; Endocrine System Diseases; Ethambutol; Furazolidone; Gastrointestinal Diseases; Hematologic Diseases; Humans; Infections; Nitrofurantoin; Respiratory Tract Diseases | 1969 |
[Mycobacterium ulcerans infection treated by Rifater, pyrazynamide, Myambutol, and surgery: a case report with a 6-year follow-up].
Topics: Anti-Bacterial Agents; Buruli Ulcer; Child; Chloramines; Combined Modality Therapy; Drug Combinations; Drug Therapy, Combination; Ethambutol; Female; Follow-Up Studies; Humans; Isoniazid; Mastectomy; Metronidazole; Mycobacterium ulcerans; Nitrofurantoin; Pleurisy; Prednisolone; Pyrazinamide; Recurrence; Rifampin; Skin Transplantation | 2008 |